Leishmaniasis, a vector-borne disease, is caused by intracellular
parasite Leishmania donovani. Unlike most intracellular
pathogens, Leishmania donovani are lodged in parasitophorous
vacuoles and replicate within the phagolysosomes in macrophages. Effective
vaccines against this disease are still under development, while the
efficacy of the available drugs is being questioned owing to the toxicity
for nonspecific distribution in human physiology and the reported
drug-resistance developed by Leishmania donovani.
Thus, a stimuli-responsive nanocarrier that allows specific localization
and release of the drug in the lysosome has been highly sought after
for addressing two crucial issues, lower drug toxicity and a higher
drug efficacy. We report here a unique lysosome targeting polymeric
nanocapsules, formed via inverse mini-emulsion technique, for stimuli-responsive
release of the drug miltefosine in the lysosome of macrophage RAW
264.7 cell line. A benign polymeric backbone, with a disulfide bonding
susceptible to an oxidative cleavage, is utilized for the organelle-specific
release of miltefosine. Oxidative rupture of the disulfide bond is
induced by intracellular glutathione (GSH) as an endogenous stimulus.
Such a stimuli-responsive release of the drug miltefosine in the lysosome
of macrophage RAW 264.7 cell line over a few hours helped in achieving
an improved drug efficacy by 200 times as compared to pure miltefosine.
Such a drug formulation could contribute to a new line of treatment
for leishmaniasis.